Dr. Joel K. Braver, MD

  • Somerville, NJ
  • Radiation oncologist
NPI1891791174
Medicare services, 2024
1,811
Medicare patients, 2024
207
Part D claims, 2024
112
Publications
3
Clinical trials
6
Practice address
110 Rehill Ave, Somerville, NJ 08876
Practice phone
Call (908) 685-2200
Professional email
Get professional email
Personal email
Get personal email
Mobile number
Get mobile number
Social profiles

Primary practice

Robert Wood Johnson University Hospital Somerset

Hospital · Somerville, New Jersey

See all 8 affiliations

Find Dr. Braver's professional email, personal email and mobile number

Dmand AI checks each channel through healthcare-specific waterfall enrichment. See what is on file with a free account, with practice phones, licenses and affiliations.

View contacts for free

Dr. Joel K. Braver is a radiation oncologist in Somerville, New Jersey

Dr. Braver practices at Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey, part of RWJBarnabas Health.

Dr. Braver's NPI, 1891791174, was assigned on June 22, 2005. Dr. Braver graduated from Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) in 1991. Dr. Braver holds New Jersey license 25MA06340800.

NPI and contact details
NPI enumeration date
June 22, 2005
NPI status
Active
Practice phone
(908) 685-2200
Professional email
Get email
Personal email
Get email
Mobile number
Get number
Sex
Male
Estimated age
61
Medical school graduation
1991

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Affiliation Data

Dr. Joel K. Braver practices at Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey

Dr. Braver's primary practice is Robert Wood Johnson University Hospital Somerset, at 110 Rehill Ave, Somerville, NJ 08876 in Somerset County. The practice phone is (908) 685-2200.

Source: Dmand AI Affiliation Data

Dr. Joel K. Braver is affiliated with 4 sites of care and 4 medical groups

Dr. Braver's primary practice is Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey, part of RWJBarnabas Health. The medical group on file is Rutgers-RWJ Scleroderma Program. Dmand AI also links Dr. Braver to 3 more group practices and clinics and 3 medical groups, each named with a free account.

See all 8 affiliations for Dr. Braver

Sources: Dmand AI Affiliation Data; and Dmand AI Org Hierarchy Data

Dmand AI tracks the EHR system at Dr. Joel K. Braver's practice

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Braver practices, 4 sites in all. Vendor and product names are available with a free account.

EHR by site
SiteEHR vendor and product
Robert Wood Johnson University Hospital SomersetAvailable with a free account
+3 more sites and 3 medical groupsAvailable with a free account

Source: Dmand AI Technology Install Data

For health IT teams

See the EHR and IT leaders at every hospital where Dr. Braver practices

Dmand AI maps EHR vendors, IT decision makers and buying committees across RWJBarnabas Health and 6.2K+ hospitals, with verified contacts in the same login.

Dr. Joel K. Braver is one of 145 radiation oncologists in New Jersey

Radiation oncology is Dr. Braver's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Braver is licensed in New Jersey.

Specialties and state licenses

  • Radiation oncology, New JerseyPrimaryLicense 25MA06340800 · taxonomy 2085R0001X

Radiation oncologists near Dr. Braver

Counts of radiation oncologists with a Dmand AI profile, by place and practice. Each opens the list.

Sources: NPPES NPI Registry (CMS); Dmand AI Professional Profile Data; and Dmand AI Peer Benchmarks

Dr. Joel K. Braver billed Medicare for 1,811 services in 2024

CMS data shows 1,811 Medicare services from Dr. Braver across 19 procedure codes in 2024, for 207 Medicare patients. Medicare paid $131,920 for them. Every service was in a facility, such as a hospital, rather than an office.

Medicare services, 20241,811
Medicare patients207
Paid by Medicare$131,920
Procedure codes19

Dr. Braver's Medicare services by type, 2023 to 2024

  • 2023
  • 2024
Imaging
2023: 1,3762024: 1,4606%
Office and hospital visits
2023: 1782024: 21119%
Other services
2023: 02024: 140

Dr. Braver compared with the New Jersey median for radiation oncologists, 2024

  • Dr. Braver
  • New Jersey median
Medicare services
1,811vs 1,813Close to median
Medicare patients
207vs 210Close to median
Part D claims
70vs 4652% above

Medians across 135 radiation oncologists in New Jersey with Dmand AI profiles that report each measure.

Dr. Braver's most billed Medicare procedure codes, 2024

CMS publishes codes billed for 11 or more Medicare patients. Each label is the code family; CPT descriptions are licensed by the AMA.

See all procedures by Dr. Braver

Need commercial claims for Dr. Braver?

Medicare shows one payer. Book a meeting to get commercial claims data for Dr. Braver and other radiation oncologists in New Jersey.

Book a meeting

Sources: Medicare Physician & Other Practitioners - by Provider and Service (CMS), 2024 data; and Dmand AI Peer Benchmarks

Dr. Joel K. Braver treated 207 Medicare patients in 2024, average age 76

CMS counts 207 Medicare patients who saw Dr. Braver in 2024. The largest group is 75 to 84, with 89 patients. 75% of them have cancer, and 75% have high blood pressure. 10% are also on Medicaid. Their average risk score is 1.47, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Braver's median patient age at 75, with 46% women.

Medicare patients, 2024207
Average age76
Average risk score1.47
Also on Medicaid10%

Dr. Braver's Medicare patients by age, 2024

CMS leaves out age groups with fewer than 11 patients.

Dr. Braver's Medicare patients by sex, 2024

  • Women11154%
  • Men9646%

Chronic conditions among Dr. Braver's Medicare patients, 2024

  1. Cancer75%
  2. High blood pressure75%
  3. High cholesterol75%
  4. Arthritis44%
  5. Diabetes33%
  6. Ischemic heart disease31%
  7. Anxiety25%
  8. Mood disorders23%

Share of Medicare patients with each condition. A patient can have several.

Dr. Braver's patients across all payers

Dmand AI patient panel data covers Medicare, Medicaid and commercial patients.

Patient panel by age, all payers

Median age 75

Patient panel by sex, all payers

  • Women46%
  • Men53%

Sources: Dmand AI Patient Panel Data; and Medicare Physician & Other Practitioners - by Provider (CMS), 2024 data

Dr. Joel K. Braver wrote 112 Medicare Part D claims in 2024

In 2024, Dr. Braver wrote 112 Medicare Part D claims for 60 patients. 96% of them were for generic drugs. CMS names the drug for 70 of them, across 2 drugs with 11 or more claims each, at $1,468 in total drug cost. In 2023, CMS named 83 claims across 2 drugs.

Part D claims, 2024112
Drugs named by CMS2
Total drug cost$1,468
Part D patients60

Dr. Braver's Part D claims by kind of drug, 2024

  • Generic107 claims96%
  • Brand-name and other5 claims4%

Dr. Braver's most prescribed drugs by claims, 2024

CMS names a drug when it has 11 or more claims. Share is of the claims for drugs CMS names.

Part D claims for drugs CMS names, 2023 to 2024

  • 2023
  • 2024
Claims for drugs CMS names
2023: 832024: 7016%

Drugs named by CMS: 2 in 2024, 2 in 2023.

See all prescribing by Dr. Braver

Sources: Medicare Part D Prescribers - by Provider and Drug (CMS), 2024 data, released May 6, 2026; and Medicare Part D Prescribers - by Provider (CMS), 2024 data

Dr. Joel K. Braver scored 88 out of 100 in Medicare's MIPS program for 2024

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Braver for performance year 2024, reported as part of a group.

Dr. Braver's MIPS scores, performance year 2024

  • 88of 100Final score
  • 70.6of 100Quality
  • 100of 100Promoting Interoperability
  • 40of 100Improvement Activities

Each score is out of 100. The final score weighs the categories CMS scored for this clinician.

Source: Clinician Public Reporting: Overall MIPS Performance (CMS), 2024 data, released September 10, 2026

For MedTech and pharma teams

Find radiation oncologists like Dr. Braver by procedure volume and prescribing

Filter 7.4M+ HCPs by Medicare procedures, Part D drugs and Open Payments history, then reach them with verified contacts in one login.

Dr. Joel K. Braver has 3 publications on record

Dmand AI links 3 papers to Dr. Braver, published from 2018 to 2020. The most frequent topics are Radiotherapy Dosage and Radiotherapy Planning, Computer-Assisted. Dr. Braver's most frequent co-authors are Laura R. Bond, MD, Joseph Aisner and Dhiren S. Dave, MD.

Papers3
Years published2018 to 2020

Dr. Braver's papers by year, 2018 to 2020

Topics Dr. Braver writes about most

  • Radiotherapy Dosage
  • Radiotherapy Planning, Computer-Assisted

Dr. Braver's most frequent co-authors

Recent publications by Dr. Braver

See all 3 publications and co-authors

See who Dr. Braver researches with

Physician Network Discovery turns co-authorship, shared hospitals and shared groups into a map of who Dr. Braver works with, so you can find a warm path to the right radiation oncologists.

How network discovery works

Sources: PubMed (National Library of Medicine); and Dmand AI Research Linkage

Dr. Joel K. Braver has worked on 6 clinical trials

Dmand AI links Dr. Braver to 6 clinical trials, 2 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Lobular and Prostatic Neoplasms. NRG Oncology sponsors the most, 2.

Clinical trials with Dr. Braver by phase

  1. NonePhase 1: no trials
  2. 2Phase 2: 2 trials
  3. 1Phase 2/3: 1 trial
  4. 2Phase 3: 2 trials
  5. NonePhase 4: no trials

Conditions in Dr. Braver's trials

  • Breast Neoplasms
  • Carcinoma, Lobular
  • Prostatic Neoplasms
  • Rectal Neoplasms
  • Urinary Bladder Neoplasms

Investigators on the most trials with Dr. Braver

Recent clinical trials with Dr. Braver

See all 6 clinical trials and co-investigators

Sources: Dmand AI Research Linkage; and ClinicalTrials.gov (National Library of Medicine)

Dr. Joel K. Braver received $449 in industry payments from 2016 to 2024

CMS Open Payments shows 16 general payments to Dr. Braver from 15 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 81% of the total. Janssen Pharmaceuticals, Inc paid the most, $85.

General payments to Dr. Braver by program year, 2016 to 2024

General payments to Dr. Braver by kind, 2016 to 2024

$449in total
  • Food and beverage$36481%
  • Education$8519%

Companies that paid Dr. Braver the most, 2016 to 2024

Share is of all general payments to this clinician.

See all payments to Dr. Braver

Source: Open Payments (CMS), 2025 data, released July 7, 2026

Dr. Joel K. Braver graduated from Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)

Dr. Braver graduated from Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) in 1991.

  1. Medical schoolRutgers R W Johnson Medical School (Cam/New Bruns/Pisc)

Source: Dmand AI Professional Profile Data

Sources for Dr. Joel K. Braver's profile data

Sources for the data on this page
Data on this pageSource
NPI, name, sex, specialty and licensesNPPES NPI Registry (CMS) (opens in a new tab)Dmand AI Professional Profile Data
Practice locations and phoneDmand AI Affiliation Data
Primary practice, affiliations and health systemDmand AI Affiliation DataDmand AI Org Hierarchy Data
Medicare services and procedure codesMedicare Physician & Other Practitioners - by Provider and Service (CMS) (opens in a new tab)
State medians for the same specialtyDmand AI Peer Benchmarks
Medicare patients and the all-payer patient panelDmand AI Patient Panel DataMedicare Physician & Other Practitioners - by Provider (CMS) (opens in a new tab)
Part D prescribingMedicare Part D Prescribers - by Provider and Drug (CMS) (opens in a new tab)Medicare Part D Prescribers - by Provider (CMS) (opens in a new tab)
MIPS scores, telehealth, assignment and procedure percentilesClinician Public Reporting: Overall MIPS Performance (CMS) (opens in a new tab)
Publications, topics and co-authorsPubMed (National Library of Medicine) (opens in a new tab)Dmand AI Research Linkage
Clinical trials and co-investigatorsDmand AI Research LinkageClinicalTrials.gov (National Library of Medicine) (opens in a new tab)
Industry paymentsOpen Payments (CMS) (opens in a new tab)
Training, board certification and membershipsDmand AI Professional Profile Data
EHR at each practice siteDmand AI Technology Install Data
Similar physiciansDmand AI Affiliation Data

Data last refreshed October 2026Report an inaccuracyRemove my information

FAQ

Frequently asked questions about Dr. Joel K. Braver

Spotted something out of date? Email hello@dmand.ai and we will check the record. Contact details live in the free trial.

What is Dr. Joel K. Braver's NPI number?

Dr. Joel K. Braver's NPI number is 1891791174. It was assigned on June 22, 2005, and it is active in the NPI Registry.

What kind of doctor is Dr. Joel K. Braver?

Dr. Joel K. Braver is a radiation oncologist in Somerville, New Jersey. The primary specialty in the NPI Registry is Radiation Oncology Physician (taxonomy code 2085R0001X).

Where does Dr. Joel K. Braver practice?

Dr. Braver practices at 110 Rehill Ave, Somerville, NJ 08876. Dr. Braver's primary practice is Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey, part of RWJBarnabas Health. Dmand AI also links Dr. Braver to 3 group practices and clinics and 3 medical groups.

What is Dr. Joel K. Braver's office phone number?

The practice phone on file for Dr. Braver is (908) 685-2200.

What is Dr. Joel K. Braver's medical license number?

Dr. Braver holds New Jersey license 25MA06340800.

Which hospitals is Dr. Joel K. Braver affiliated with?

Dr. Braver practices at Robert Wood Johnson University Hospital Somerset in Somerville, New Jersey.

What medical group is Dr. Joel K. Braver part of?

Dr. Braver is linked to Rutgers-RWJ Scleroderma Program. Dmand AI links Dr. Braver to 3 more medical groups.

Does Dr. Joel K. Braver accept Medicare?

Yes. CMS data shows Dr. Braver billed Medicare for 1,811 services in 2024.

What is Dr. Joel K. Braver's MIPS score?

Dr. Braver's MIPS final score for performance year 2024 is 88 out of 100, reported as part of a group.

How many Medicare patients does Dr. Joel K. Braver see?

CMS counts 207 Medicare patients who saw Dr. Braver in 2024, with an average age of 76.

Show 7 more questionsShow fewer questions

What services does Dr. Joel K. Braver bill to Medicare?

In 2024, Dr. Braver's most billed Medicare services were radiation oncology (77014), radiation oncology (77427) and radiation oncology (77300).

Where did Dr. Joel K. Braver go to medical school?

Dr. Braver graduated from Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) in 1991.

What drugs does Dr. Joel K. Braver prescribe most?

In 2024 Medicare Part D data, Dr. Braver's most prescribed drugs by claims were Mometasone Furoate and Tamsulosin HCl.

Has Dr. Joel K. Braver received payments from drug or device companies?

CMS Open Payments shows $449 in general payments to Dr. Braver from 15 companies from 2016 to 2024. The largest total came from Janssen Pharmaceuticals, Inc.

How long has Dr. Joel K. Braver been practicing?

Dr. Braver graduated from medical school in 1991, 35 years ago.

Does Dr. Joel K. Braver do research?

Dmand AI links 3 publications to Dr. Braver, published from 2018 to 2020. Dr. Braver has worked on 6 clinical trials.

Who does Dr. Joel K. Braver publish with?

Dr. Braver's most frequent co-authors are Laura R. Bond, MD (2 shared papers), Joseph Aisner (1 shared paper) and Dhiren S. Dave, MD (1 shared paper).

Selling to radiation oncology practices?

See radiation oncologists in New Jersey by site of care and group

Find the practices, groups and hospitals they work with, and the right people to contact at each.

  • 30 days free
  • Self-serve
  • No credit card

Cookie settings

Turn each category on or off. Your choice is kept for 12 months and you can change it here at any time.

Necessary

Always on. Sign-in, security, downloads you asked for, your cookie choice, and the page that led to a signup.

View cookies (6)
  • dm_consentDmand AI. Your cookie choices and whether your browser sent a Global Privacy Control signal. 12 months.
  • dm_ft, dm_ltDmand AI. The first and the latest page you arrived on, with the date, so a signup is credited to the page that worked. 90 days, 30 days.
  • dm_fs, dm_lsDmand AI. The first and the latest source of a visit (a search engine, a campaign or the site that linked here). 90 days, 30 days.
  • dm_dl, dm_dl_okDmand AI. After you give an email address for a download, lets you download files without being asked again. 30 days.
  • Session and CSRF cookiesDmand AI (app.dmand.ai). Sign-in and form protection in the application. Session.
  • __cf_bm, cf_clearanceCloudflare. Tells people from automated traffic and keeps the site available. 30 minutes; cf_clearance while a security check is valid.

Analytics

On unless you turn it off. How pages are used, in aggregate, and recordings of how pages are used.

View cookies (6)
  • Google Tag ManagerGoogle. Loads the analytics and marketing tags that are on. Sets no cookie of its own and does not load when both categories are off. n/a.
  • _ga, _ga_<container-id>Google Analytics 4. Visits and page views in aggregate on dmand.ai. 2 years.
  • _clck, _clskMicrosoft Clarity. Recordings and heatmaps of how pages are used, with form fields masked. 1 year, 1 day.
  • CLID, MUID, ANONCHK, MR, SMMicrosoft (clarity.ms). Set by Microsoft when Clarity loads, to recognize a browser across sites that use Clarity. Up to 1 year.
  • None (cookieless)Ahrefs Analytics. Page views in aggregate. n/a.
  • ph_<project>_posthogPostHog. Product usage, errors and performance in app.dmand.ai, used to fix bugs and improve features. 365 days.

Marketing

On unless you turn it off, and always off when your browser sends a Global Privacy Control signal. A visitor identification service tells our sales team which companies and people visit.

View cookies (6)
  • _reb2buid, _reb2butkRB2B. Recognizes a returning browser for visitor identification. 360 days, 1 year.
  • _reb2bgeoRB2B. The location used to decide whether a visit can be identified. 20 days.
  • _reb2brefRB2B. The page or site that referred the visit. 15 days.
  • _reb2bfxf, _reb2btd, _reb2bliRB2B. Links the visit to an identified business profile. 1 month.
  • _reb2bresolveRB2B. Holds a match while it is being resolved. 2 days.
  • _reb2sessionID, _reb2bloadedRB2B. The current visit, and a guard against loading the script twice. 30 minutes, 1 second.

Functional

On unless you turn it off. Remembers choices such as a collapsed section.

View cookies (none today)